ASGE Recognized Industry Associate (ARIA) Training Program for Regeneron | June 2022-June28 Session 11B - Pathophysiology and Current Treatment of EoE Q&A

June28 Session 11B - Pathophysiology and Current Treatment of EoE Q&A

Video Transcription

Video Summary

In this video, a healthcare provider discusses their approach to treating patients with eosinophilic esophagitis (EOE). They mention that if a patient does not show progress within two months of starting a new medication, there should be some histological response or diameter change. They also note that it may not take two months for symptoms and eosinophil count to improve after medication initiation. The provider emphasizes the importance of personalized medicine for EOE and mentions that some patients may have a quick and positive response to PPIs, while others may require additional biologic therapies like Dupixent. The provider also discusses the mechanisms of different biologics, the need for repeated endoscopies, the use of esophageal dilation for strictures, and the lack of immunosuppression associated with Dupixent compared to other biologics. They stress the importance of personalized treatment plans and close monitoring of patients with EOE. The exact duration of treatment with PPIs and Dupixent can vary based on individual patient needs and response. Overall, the video provides insights into the management and considerations for patients with EOE.

Keywords

eosinophilic esophagitis

personalized medicine

biologic therapies

Dupixent

patient monitoring